Candrice Heath, MD, shares clinical pearls about the treatment of acne in pediatric patients with skin of color, including:

What is your personal approach to treating acne in patients with skin of color?

Can you tell us about the approved and emerging therapies for treatment of acne in pediatric patients?

Have any of them been studied in patient populations with skin of color?

Can you explain why it is important to treat both acne and post-inflammatory hyperpigmentation, particular in patients of color?

How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?

Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:

• What are the inside-out and outside-in mechanisms of AD?
• Is there a difference between these mechanisms across the age spectrum – from children to adults?
• Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?

Leon Kircik, MD discusses the potential role of emerging AD treatments, including:

• Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
• What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
• Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
• In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?

Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:

• How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
• Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
• How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?

Neal Bhatia, MD discusses the potential role of JAKis in AD, including:

• What changes would JAKis bring to the treatment of AD in the near future?
• What are some JAKis currently under clinical development for AD?
• Do you foresee that JAKis will play a role in both adult and pediatric AD?
• Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
• What are the long-term implications for dermatology practice?

Jonette Keri, MD, PhD, shares some highlights about acne evaluation and treatment across the age spectrum, including:

• How do we differentiate and grade acne across the age spectrum, from newborns to preteens?

• When is it necessary to refer, particularly to endocrinology or other specialties, for childhood acne that may be associated with an underlying endocrine disorder?

• What should we be using more of and less of in treating acne across the age groups?

• How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?

Diane Berson, MD, shares additional clinical pearls on the treatment of adult female acne, including:

• What are some typical acne presentations seen in adult women?

• Can acne in women persist beyond menopause?

• Can some of the newer non-oral contraceptives exacerbate acne flares? What are the options in this case?

• Is there a concern with hyperkalemia in patients taking spironolactone for acne?

• What should dermatologists keep in mind while treating acne in adult women?

James Del Rosso, MD, shares clinical pearls about common controversies and recent developments in acne therapy, including:

• What is your approach to minimizing antibiotic resistance in acne?
• Are the newer antibiotics better in terms of resistance?
• Why are dermatologists hesitant in using oral isotretinoin?
• What are some of the advantages with the newer topical retinoids?
• Should we pay more attention to truncal acne?

Michael Gold, MD, discusses additional takeaways on laser and light therapy for acne, including:

• How do you explain the absence of light and laser therapies from the global alliance acne treatment algorithm? Do you think that there is enough evidence to recommend their addition to the treatment guidelines?
• How do lasers/light therapies for acne challenge the current treatment status quo? How do they fit in with existing treatments?
• For what patient profiles (in terms of severity or type of acne) are they more appropriate?
• What are some key devices for acne treatment?